To Evaluate the Efficacy and Safety of NMN as an Anti-ageing Supplement in Middle Aged and Older (40-65 Years) Adults

Completed 90 enrolled Abinopharm, Inc ProRelix Research · collab

RandomizedParallel-groupQuadruple-blindOther

Summary

It will be a two-part study. Part I will be six arms; randomized, double blind, parallel design, placebo-controlled dose ranging study. Part II will be open-label single dose study at the highest dose. A total of 90 Subjects (Part 1 \& Part 2) will be enrolled in the study. The Part 1 group subjects (80 Subjects) shall be randomly distributed between the six arms, i.e. 20 Subjects each in IP arms, and 7, 7 and 6 subjects in corresponding placebo arms. All Part 2 Group subjects (10 Subjects) will be assigned into the cluster where all receive the maximum NMN dose (900 mg)

Timeline

Start: 2021-05-25
Primary completion: 2021-09-09
Completion: 2021-09-09

Publications

Yi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, Thasma S, Andhalkar N, Avhad G, Kumbhar V. The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023 Feb;45(1):29-43. doi: 10.1007/s11357-022-00705-1. Epub 2022 Dec 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Nicotinamide Mononucleotide	Unknown	300 mg	Oral
Comparator	Nicotinamide Mononucleotide	Unknown	600 mg	Oral
Comparator	Nicotinamide Mononucleotide	Unknown	900 mg	Oral

Indications

No indication recorded.